Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF) boosted its finances by almost A$19 million shortly before Christmas through the exercising of underwritten listed options.
Total gross proceeds from the 2,370,209 listed options exercise that were on issue on November 1, 2021, and expired on December 18, 2021, was A$18,961,672.
Applications to exercise 1,922,064 options from existing holders were received for proceeds of A$15,376,512.
Evolution Capital Pty Ltd, under an underwriting agreement with the company, exercised its right over the remaining shortfall of 448,145 options for gross consideration of A$3,585,160.
READ: Anteris Technologies buoyed by follow-up milestone from first-in-human DurAVR™ heart valve study
Earlier this month the company reported that all five patients from its first-in-human DurAVR™ heart valve study passed the seven-day follow-up mark.
This means that when the ASX-lister checked in with the study’s patients seven days after their procedure, all were responding in line with clinical expectations.
Anteris reports that all five patients have been assessed and their performance status is excellent.
Now, the biotech is looking to the 30-day milestone — the next big check-up in the follow-up pipeline.
About Anteris Technologies
AVR is a structural heart company that delivers clinically superior and durable solutions through better science and better design. Its focus is developing next-generation technologies that help healthcare professionals reproduce consistent life-changing outcomes for patients.
Its DurAVR™ 3D single-piece aortic heart valve replacement addresses the needs of tomorrow’s younger and more active aortic stenosis patients by delivering superior performance and durability through innovations designed to last the remainder of a patient’s lifetime.
The proven benefits of Anteris' patented ADAPT® tissue technology, paired with the unique design of its DurAVR™ 3D single-piece aortic heart valve, have the potential to deliver a game-changing treatment to aortic stenosis patients worldwide and provide a much-needed solution to the challenges facing doctors today.